A Stratified, Multicenter Phase II Trial of Transdermal CR1447 (4-OH-testosterone) in Endocrine Responsive-HER2 Negative and Triple Negative-androgen Receptor Positive Metastatic or Locally Advanced Breast Cancer
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 28 Jan 2019
Price : $35 *
At a glance
- Drugs 4-hydroxytestosterone (Primary)
- Indications Adenocarcinoma; Advanced breast cancer
- Focus First in man; Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 27 Jul 2018 Status changed from recruiting to active, no longer recruiting.
- 08 Feb 2017 Planned primary completion date changed from 1 Oct 2018 to 1 Dec 2018.